GLP-1s anti-obesity drugs effective at reducing addiction and substance use such as alcohol use

‍

Substance use disorders (SUDs) present significant treatment challenges, with high relapse rates and limited long-term success. Relapse rates for SUDs range between 40% and 60%, indicating that many individuals return to substance use after treatment. (Addiction Group) For example, approximately 68.4% of individuals treated for alcohol use disorder (AUD) relapse within four years. (Addiction Group) Additionally, less than 43% of individuals entering treatment for drug and alcohol use complete it, highlighting the need for more effective interventions. (American Addiction Centers)

Current treatments for SUDs include behavioral therapies, counseling, and medications like naltrexone, methadone, and buprenorphine. While these approaches can be effective, their success varies, and many individuals do not achieve sustained recovery. For instance, naltrexone has been associated with a 14% reduction in alcohol-related hospitalizations, underscoring the necessity for more effective treatments. (New York Post)

Emerging evidence suggests that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications used for type 2 diabetes and obesity, may reduce cravings for substances like alcohol and opioids. Studies indicate that individuals using GLP-1 RAs have a 50% lower risk of developing or relapsing into AUD. (New York Post) Additionally, research involving over 500,000 patients found that GLP-1 RAs reduced opioid use disorder by 40% and alcohol use disorder by 50%. (MarketWatch) These findings suggest that GLP-1 RAs could offer a novel approach to treating SUDs by modulating the brain’s reward pathways and reducing cravings.

While these results are promising, further research is needed to confirm the efficacy of GLP-1 RAs in treating SUDs and to understand their mechanisms of action. Nonetheless, GLP-1 RAs represent a potential advancement in addiction treatment, offering hope for more effective interventions in the future.

‍

Mechanism of Action

‍

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are medications originally designed to treat type 2 diabetes and obesity. Recent research suggests they may help reduce cravings for substances like alcohol and opioids. Here’s how they might work, based on neuroscience and psychiatric science.

Addiction involves the brain’s reward system, particularly a region called the mesolimbic dopamine pathway. This pathway drives the pleasurable feelings from drugs, alcohol, and even food. In people with addiction, this system becomes overactive, making cravings and relapse more likely.

GLP-1 RAs act on the brain in a few ways:

1. Regulating Dopamine Release: These medications influence dopamine, a “feel-good” chemical in the brain. By modulating GLP-1 receptors in the reward system, such as the ventral tegmental area (VTA) and nucleus accumbens, they reduce the excessive dopamine release caused by substances like alcohol. This can make the substance feel less rewarding.
2. Curbing Cravings: GLP-1 RAs affect brain areas like the hypothalamus, which controls hunger and impulse control. For example, they can reduce the desire to binge drink by suppressing overactive craving circuits.
3. Improving Impulse Control: GLP-1 RAs may also strengthen connections in the prefrontal cortex, the brain’s decision-making hub. A stronger prefrontal cortex can help people resist the urge to use substances.
4. Reducing Withdrawal Stress: Substance use increases stress hormones, which can drive relapse. GLP-1 RAs might reduce this stress response, making recovery easier.

Studies in animals and humans show these medications can blunt the effects of addictive substances, potentially offering a new tool in treating addiction. For example, a study found that GLP-1 RAs reduced alcohol consumption in mice by 40%. Another trial in humans showed participants experienced fewer cravings and less pleasure from drinking.

These findings highlight the exciting potential of GLP-1 RAs as a breakthrough in addiction treatment.

‍

Summary of JAMA Research Letter:
‍

Recent research explores whether anti-obesity medications (AOMs) might help reduce alcohol consumption. This study examined 14,053 adults enrolled in a telehealth weight management program who started using AOMs. These included glucagon-like peptide-1 receptor agonists (GLP-1 RAs), bupropion-naltrexone, and metformin.

Before and after beginning AOM treatment, participants reported their weekly alcohol use. About half of the participants drank alcohol at baseline. Among those, nearly 45% reduced their drinking after starting AOMs. People with higher obesity levels and heavier alcohol use were most likely to cut back.

Researchers noted differences between medications. Bupropion-naltrexone appeared particularly effective for reducing alcohol consumption, likely because naltrexone reduces alcohol cravings. GLP-1 RAs may also play a role by dampening alcohol’s pleasurable effects, similar to their impact on food. Even metformin, though not directly targeting cravings, was associated with lower alcohol use, potentially due to participants’ commitment to healthier habits in the program.

This study highlights the potential of AOMs as tools for managing alcohol use, especially in individuals seeking weight loss. However, further research, such as randomized trials, is needed to confirm these effects and compare AOMs with non-drug approaches.

‍

Related Keywords: 

• Anti-obesity medications (AOMs)
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
• Alcohol use disorder (AUD)
• Substance use disorder (SUD)
• Weight loss pharmacotherapy
• Bupropion-naltrexone
• Metformin
• Semaglutide
• Liraglutide
• Dulaglutide
• Tirzepatide
• Leptin resistance
• Reward pathways
• Dopamine signaling
• Behavioral addictions
• Pharmacological treatment

Telehealth weight management
• Self-reported alcohol use
• Body mass index (BMI)
• WeightWatchers (WW) Clinic
• Behavioral health interventions
• Alcohol consumption reduction
• Obesity classes
• Multivariate logistic regression
• Health behavior change
• Randomized controlled trials
• Placebo-controlled studies
• Nonpharmacological interventions

‍

‍